Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CEA concentrations exceeding 5 ng/mL cut-off point indicated carcinomas, regardless of pleural involvement, which gave a sensitivity of 62% and specificity of 100% for carcinoma.
|
31028099 |
2019 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
AA-Cur elicited moderate anti-tumor activity toward colon MC38-CEA or breast 4T1 carcinomas.
|
31564877 |
2019 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Serum carcinoembryonic antigen (CEA) is used as an indicator of tumor progression in a variety of carcinomas.
|
28314278 |
2017 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The measurement of mural nodule size in all types of carcinomas and carcinoembryonic antigen level in the pancreatic juice in mixed and main duct carcinomas might play important roles in predicting invasive intraductal papillary mucinous carcinoma, but further large studies are needed to confirm these results.
|
28122068 |
2017 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.
|
27581603 |
2016 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Antitumor studies were performed in CEA-Tg mice bearing CEA-transfected MC38 murine colon carcinomas (MC38-CEA), treated either concurrently or sequentially with sunitinib and vaccine.
|
21633954 |
2012 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PANVAC consists of rV, rF-CEA-MUC1-TRICOM; the expression of the two pan-carcinoma transgenes CEA and MUC-1 renders PANVAC vaccination applicable for therapeutic applications for a range of human carcinomas.
|
22595052 |
2012 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Carcinoembryonic antigen (CEA) is a potential target for antigen-specific immunotherapy, as it is frequently overexpressed in human carcinomas.
|
20386466 |
2010 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Construction, expression and characterization of a dual cancer-specific fusion protein targeting carcinoembryonic antigen in intestinal carcinomas.
|
19686851 |
2010 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas.
|
18937552 |
2009 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Total RNA was isolated from 18 lung carcinomas with positive carcinoembryonic antigen (CEA) and mucin-1 (MUC1) staining, as identified by immunohistochemistry.
|
19811429 |
2009 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Carcinoembryonic antigen (CEA) is expressed on human colon carcinomas, is well characterized, and continues to be a promising target for cancer immunotherapy in humans.
|
18812201 |
2008 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
On the other hand, 85% of non-small cell lung carcinomas stained for CEA, whereas none of the ovarian clear cell carcinomas did (P < 0.001).
|
17413979 |
2007 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Downregulation of carcinoembryonic antigen-related cell adhesion molecule (CEACAM1), a cell adhesion molecule with tumor suppressing properties has been observed in a high percentage of carcinomas of the endometrium and other malignancies.
|
16332726 |
2006 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The objective of this study was both to design recombinant vectors in which the suicide gene E. coli purine nucleoside phosphorylase (ePNP) is under the control of either CEA or MUC1 promoter sequences and to investigate on experimental pancreatic carcinomas the selective killing effects of the conditional ePNP/prodrug (MePdR) system.
|
15580629 |
2005 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
|
15613691 |
2005 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The percentages of abnormal expression of each protein in D-type, UT-type and UP-type carcinomas were as follows: 27% (38/143), 17% (17/98) and 15% (5/33) for p53; 27% (39/143), 19% (19/98) and 18% (6/33) for p16; 38% (54/143), 44% (43/98) and 24% (8/33) for hMLH1; 15% (22/143), 5% (5/98) and 0% (0/33) for c-erbB-2; and 22% (31/143), 35% (34/98) and 70% (23/33) for CEA.
|
16254038 |
2005 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Carcinoembryonic antigen (CEA) has been suggested as a metastatic activator in colorectal carcinoma, whereas the E-cadherin expression is downregulated in a variety of carcinomas.
|
14592671 |
2003 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The present approach to manipulating antigen presentation may open new possibilities for immunotherapy against colon and other CEA-secreting carcinomas.
|
12719706 |
2003 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, the newly identified helper T-cell epitope was found to overlap with a previously described HLA-A24-restricted CTL epitope, CEA(652-660), which could facilitate the development of a therapeutic vaccine capable of eliciting both CTL and T helper responses in patients suffering from epithelial carcinomas.
|
12374692 |
2002 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We have recently demonstrated that the increased cell surface levels of CEA and CEACAM6 in purified human colonocytes from freshly excised, well to poorly differentiated colon carcinomas are inversely correlated with the degree of cellular differentiation.
|
11896570 |
2002 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Carcinoembryonic antigen (CEA) is expressed on approximately 95% of colorectal, gastric, and pancreatic tumors, and on the majority of breast, non-small cell lung, and head and neck carcinomas.
|
11289125 |
2001 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The resulting hybrid mice developed gastrointestinal polyps in 6-8 months that progressed to invasive carcinomas with a similar pattern of dysplasia and CEA expression as observed in human colorectal cancer.
|
11731437 |
2001 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
On the other hand, slightly higher CEA-specific T cell responses were observed in cancer patients with CEA-expressing carcinomas than in healthy blood donors.
|
11129322 |
2000 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that mammaglobin B and CEA could be useful RT-PCR markers for the detection of lymph node micrometastases in biliary tract carcinomas.
|
10873083 |
2000 |